Gordon was admitted to practise as a solicitor in Australia in 2012 and in Hong Kong in 2013. He joined the firm in 2015.
Gordon has experience in handling a wide range of corporate and commercial matters, including pre-IPO restructuring and financing, Hong Kong and U.S. IPOs, mergers and acquisitions, loan and financing transactions, corporate governance and general compliance for listed companies as well as private enterprises.
Gordon is the Non-Executive Director of China Regenerative Medicine International Ltd (Stock Code: 8158), the Independent Non-Executive Director of Sterling Group Holdings Limited (Stock Code: 1825) and CROSSTEC Group Holdings Limited (Stock Code: 3893). He is also the Company Secretary of Sunshine 100 China Holdings Ltd (Stock Code: 2608), Mabpharm Limited-B (Stock Code: 2181) and Sundy Service Group Co. Ltd (Stock Code: 9608).